AIDS by HUGHES, R. A. et al.
CONCISE COMMUNICATIONLong terms trends in CD4R cell counts, CD8R cell
counts, and the CD4R : CD8R ratio
Rachael A. Hughesa, Margaret T. Maya, Kate Tillinga,b, Ninon Taylorc,
Linda Wittkopd,e, Peter Reissf,g,h,i, John Gillj, Philipp Schommersk,
Dominique Costagliolal, Jodie L. Guestm, Viviane D. Liman,o,
Antonella d’Arminio Monfortep, Colette Smithq, Matthias Cavassinir,s,






















original work is propObjective: Model trajectories of CD4þ and CD8þ cell counts after starting combination
antiretroviral therapy (ART) and use the model to predict trends in these counts and the
CD4þ : CD8þ ratio.
Design: Cohort study of antiretroviral-naı̈ve HIV-positive adults who started ART after
1997 (ART Cohort Collaboration) with more than 6 months of follow-up data.
Methods: We jointly estimated CD4þ and CD8þ cell count trends and their correlation
using a bivariate random effects model, with linear splines describing their population
trends, and predicted the CD4þ : CD8þ ratio trend from this model. We assessed
whether CD4þ and CD8þ cell count trends and the CD4þ : CD8þ ratio trend varied
according to CD4þ cell count at start of ART (baseline), and, whether these trends
differed in patients with and without virological failure more than 6 months after starting
ART.
Results: A total of 39 979 patients were included (median follow-up was 53 months).
Among patients with baseline CD4þ cell count at least 50 cells/ml, predicted mean
CD8þ cell counts continued to decrease between 3 and 15 years post-ART, partly
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1362 AIDS 2018, Vol 32 No 10follow-up, normalization of the predicted mean CD4þ : CD8þ ratio (to >1) was only
observed among patients with baseline CD4þ cell count at least 200 cells/ml. A higher
baseline CD4þ cell count predicted a shorter time to normalization.
Conclusion: Declines in CD8þ cell count and increases in CD4þ : CD8þ ratio occurred
up to 15 years after starting ART. The likelihood of normalization of the CD4þ : CD8þ
ratio is strongly related to baseline CD4þ cell count.
Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc.AIDS 2018, 32:1361–1367Keywords: CD4þ cell count, CD4þ : CD8þ ratio, CD8þ cell count, combination
antiretroviral therapy, HIVIntroduction
Combination antiretroviral therapy (ART) has led to
substantial increases in the life-expectancy of HIV-
positive individuals [1]. Substantial declines in rates of
AIDS have led to increased interest in non-AIDS, age-
related diseases such as cardiovascular diseases, non-AIDS
cancers, kidney disease and neurocognitive decline [2–7],
rates of which are higher than in the general population
[8]. HIV infection leads to persistent immune activation
and inflammation, which may accelerate immunosenes-
cence (deterioration of the immune system due to ageing)
[9]. In the general population, a low CD4þ : CD8þ ratio
is a surrogate marker for immunosenescence and an
independent predictor of all-cause mortality [10,11].
Among HIV-positive individuals, low CD4þ : CD8þ
ratio has been associated with higher levels of immuno-
senescence and inflammation, although the results
regarding whether a low or inverted CD4þ : CD8þ ratio
predicts non-AIDS-related morbidity and mortality have
been conflicting [12,13].
The benefits of ART for recovery of CD4þ cell counts are
well documented [14–16]. However, few studies have
investigated long-term trends in CD8þ cell counts [17–21]
and in CD4þ : CD8þ ratio [17–24] after starting ART,
with almost all based on small (<150) or moderate (<2000)
sample sizes. Given the potential health implications of
elevated CD8þ cell counts and CD4þ : CD8þ ratios below
1 [19,20,25], more information is needed about their long-
term trends in treated patients.
Our aims were to quantify long-term trends in CD8þ cell
counts and CD4þ : CD8þ ratios, up to 15 years after
starting ART, in a large cohort of antiretroviral-naı̈ve
individuals starting ART, and assess the impact of baseline
CD4þ cell count on these trends.Methods
Study patients
The ART Cohort Collaboration (ART-CC) is an
international collaboration between prospective cohortstudies of HIV-positive individuals residing in Europe
and North America, described elsewhere [26] and at
www.art-cohort-collaboration.org. Cohorts enrolled
HIV-positive ART-naı̈ve individuals aged at least 16 years
starting treatment with a combination of at least three
antiretroviral drugs. All cohorts provided anonymized
data on a predefined set of demographic, laboratory and
clinical variables, which were then pooled and analysed
centrally. The NHS Health Research Authority South
West, Cornwall and Plymouth Research Ethics Com-
mittee, UK, approved the study (REC reference 12/SW/
0253).
Eligible patients were antiretroviral-naı̈ve, started
ART after 1997, had at least one CD4þ and CD8þ
measurement within the baseline period (defined as 90
days before to 6 days after starting ART) and one or more
CD4þ and CD8þ measurements 6 months after starting
ART.
Statistical analyses
CD4þ and CD8þ cell counts were natural-log trans-
formed (zero counts were set to 1), to stabilize the
variance and meet normality assumptions. When
modelling the relationships of log-CD4þ and log-
CD8þ with time, we considered fractional polynomials
of one to four degrees with powers2, 1,0.5, 0, 0.5,
1, 2, 3 (power zero is interpreted as natural-log
transformation) and linear spline models with two to
five knots. We compared model fit using the Bayesian
information criterion and the percentage of fitted values
within 5% of observed values. We jointly modelled log-
CD4þ and log-CD8þ using a bivariate random effects
model. We included patient-level random effects for the
intercept and trajectory terms, thus allowing trajectories
to vary between patients. We allowed patient-level and
measurement-level residuals to be correlated, thus
allowing associations between CD4þ and CD8þ trajec-
tories at both patient and measurement levels. Using the
best fitting model, we estimated predicted means of
log-CD4þ and log-CD8þ, which when exponentiated
became geometric means of CD4þ and CD8þ cell
counts, respectively. We calculated the difference between
predicted means of log-CD4þ and log-CD8þ, which
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Table 1. Characteristics of the 39 979 patients eligible for analysis.
Baseline CD4þ cell count (cells/ml)
<25 25–49 50–99 100–199 200–349 350–499 500
Number of patients 2510 1779 3018 7455 14 141 6593 4483
Median (IQR) age (years) 38 (12) 40 (13) 39 (14) 39 (14) 38 (14) 38 (14) 37 (15)
Male (%) 76 75 73 70 72 73 70
Route of HIV infection (%)
Homo/bisexual 27 31 33 34 41 45 43
IDU 11 11 11 11 9 9 9
Heterosexual 51 46 45 44 41 37 37
Other/not known 11 12 11 10 9 10 11
Median (IQR) baseline viral load
(log10 copies/ml)
5.30 (0.79) 5.31 (0.81) 5.14 (0.85) 4.91 (0.94) 4.65 (1.00) 4.49 (1.35) 4.01 (2.57)
Median (IQR) baseline CD8þ (cells/ml) 340 (320) 480 (421) 610 (501) 749 (540) 900 (594) 981 (674) 1062 (715)
Median (IQR) follow-up (months) 64 (78) 64 (78) 61 (74) 62 (66) 50 (59) 41 (69) 47 (81)
IQR, interquartile range.were exponentiated to derive predicted geometric mean
CD4þ : CD8þ ratio. CD4þ : CD8þ ratios greater than 1
were defined as normalized.
Patients were classified by their baseline CD4þ (<25, 25–
49, 50–99, 100–199, 200–349, 350–499, 500 cells/
ml) and CD8þ (<500, 500–749, 750–999, 1000 cells/
ml) cell counts. Patients with multiple measurements
within the baseline period were classified using the
measurement closest to their ART start date.
We included covariates sex, age at start of ART, risk
transmission group, ethnicity and baseline CD4þ and
CD8þ groups. To allow CD4þ and CD8þ trajectories to
vary between baseline CD4þ groups, we included
interactions between baseline CD4þ group and the
intercept and trajectory terms.
Virological failure was defined as a HIV RNA measure-
ment exceeding 1000 copies/ml, regardless of whether a
patient had interrupted treatment. We generated a binary,
time-independent variable denoting whether, from 6
months after starting ART, patients experienced at least
one virological failure (virologically unsuppressed) or all
viral load measurements were 1000 copies/ml or less
(virologically suppressed). We predicted geometric means
of CD4þ and CD8þ cell counts separately among patients
classified as virologically suppressed and unsuppressed by
including three-way interactions between the intercept
and trajectory terms, baseline CD4þ group and viral
suppression indicator.
In sensitivity analyses, we predicted geometric mean
CD4þ and CD8þ cell counts separately among patients
who started treatment before 2004 and from 2004
onwards, and included the 6% of patients who had no
CD4þ or CD8þ measurements 6 months post-ART.
Analyses were conducted using STATA/MP, version 14
(StataCorp LLC, College Station, Texas, USA) [27], with
the runmlwin command [28] to run software MLwiN,version 3.01 (Centre for Multilevel Modelling, Univer-
sity of Bristol, Bristol, UK) [29] from within STATA.Results
Of 110 098 patients included in ART-CC up to 31
December 2013, 15% were excluded as they started ART
before 1998 or before entering the study, 43% without
CD4þ or CD8þ measurements within the specified
baseline period, and 6% as they had no CD4þ or CD8þ
measurement after 6 months since starting ART. Table 1
presents characteristics of the remaining 39 979 eligible
patients according to baseline CD4þ cell count. Most
were men, approximately 40% were heterosexual and the
median age at start of ART was about 40 years. Higher
baseline CD4þ cell count predicted higher baseline
CD8þ cell count, with substantial reductions in median
CD8þ cell count as baseline CD4þ cell count decreased
from 100–199 to less than 25 cells/ml.
Figure 1 shows trajectories of geometric mean CD4þ cell
count, CD8þ cell count and CD4þ : CD8þ ratio
according to baseline CD4þ group, predicted using the
best fitting models (linear splines, with knots at 1, 21, 48
and 75 months for CD4þ cell count, and at 6 weeks, 9, 36
and 66 months for CD8þ cell count). Among patients
with baseline CD4þ cell count less than 200 cells/ml,
mean CD8þ cell counts increased steeply during the first
6 weeks of treatment, slowly decreased between 6 weeks
and 9 months post-ART, slowly increased between 9
months and 3 years, and slowly decreased between 3 and 6
years. For example, among patients with baseline CD4þ
cell count less than 25 cells/ml, the estimated ratios of
geometric mean CD8þ cell count per month were
1.6724 (95% confidence interval 1.6509, 1.6938) during
the first 6 weeks of treatment, 0.9971 (0.9948, 0.9994)
between 6 weeks and 9 months post-ART, 1.0045
(1.0038, 1.0051) between 9 months and 3 years and
0.9969 (0.9963, 0.9975) between 3 and 6 years. Lower
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Fig. 1. Predicted geometric mean CD4R cell count trajectories, predicted geometric mean CD8R cell count trajectories and
derived predicted geometric mean CD4R : CD8R ratio trajectories, according to baseline CD4R group.baseline CD4þ cell count predicted larger declines in
CD8þ cell count between 3 and 6 years post-ART (refer
to Appendix Table 1, http://links.lww.com/QAD/
B274). Among patients with baseline CD4þ cell count200–499 cells/ml, mean CD8þ cell counts slowly
increased during the first 6 weeks, steeply decreased
from 6 weeks to 9 months post-ART and then slowly
decreased from 9 months post-ART. For example, among
Trends in CD4R : CD8R ratio on ART Hughes et al. 1365patients with baseline CD4þ cell count 200–349 cells/ml,
the estimated ratios of geometric mean CD8þ cell count
per month were 1.0076 (1.0022, 1.0130) during the first
6 weeks, 0.9805 (0.9795, 0.9814) between 6 weeks and
9 months, 0.9988 (0.9985, 0.9991) between 9 months
and 3 years, 0.9993 (0.9991, 0.9996) between 3 and
6 years and 0.9989 (0.9986, 0.9991) from 6 years to end of
follow-up. Among patients with baseline CD4þ cell
count at least 500 cells/ml, mean CD8þ cell counts
steeply decreased during the first 9 months post-ART,
levelled-off between 9 months and 3 years, and then
slowly decreased thereafter. From 6 years post-ART,
mean CD8þ cell count plateaued among patients with
baseline CD4þ cell count less than 50 cells/ml, but
continued decreasing among patients with baseline
CD4þ cell count at least 50 cells/ml.
Mean CD4þ cell counts increased throughout follow-up,
except for patients with baseline CD4þ cell count at least
350 cells/ml in whom mean CD4þ cell counts plateaued
or slowly decreased between 21 months and 6 years post-
ART. Among all patients, the mean CD4þ : CD8þ ratio
trajectory followed the same pattern as the mean CD4þ
cell count, indicating that changes in CD4þ : CD8þ ratio
were mainly driven by changes in CD4þ cell count.
However, during periods of decreasing CD8þ cell count,
relative increases in the mean CD4þ : CD8þ ratio were
higher than those of mean CD4þ cell count. Among
patients with baseline CD4þ cell count less than 50 cells/
ml, increases in mean CD4þ : CD8þ ratio 6 years post-
ART were only driven by CD4þ cell count increases,
whereas among the remaining patients, increases in the
mean CD4þ : CD8þ ratio were driven by both increasing
CD4þ cell counts and decreasing CD8þ cell counts.
During the 15-year follow-up period, the mean
CD4þ : CD8þ ratio only exceeded 1 among patients
with baseline CD4þ cell count at least 200 cells/ml:
higher baseline CD4þ cell count predicted a shorter time
to mean CD4þ : CD8þ ratio> 1.
Trends in mean CD8þ cell count and CD4þ : CD8þ ratio
were similar between patients who were and were not
virologically suppressed from 6 months post-ART
(Appendix Tables 2 and 3, http://links.lww.com/
QAD/B274). However, changes in mean CD8þ cell
counts were more beneficial (smaller mean increases and
larger mean decreases), and increases in the mean
CD4þ : CD8þ ratio were larger, among virologically
suppressed patients compared with those not suppressed.
Trends in mean CD4þ cell counts, CD8þ cell counts and
CD4þ : CD8þ ratio were similar among patients who
started treatment before 2004 and those who started 2004
onwards. However, patients starting treatment from 2004
onwards had higher mean CD4þ cell counts, lower mean
CD8þ cell counts and higher CD4þ : CD8þ ratios
throughout follow-up (results not shown). Including
the 6% of patients who did not have any CD4þ or CD8þmeasurements 6 months, post-ART had minimal effect
on the results (results not shown).Discussion
Using data from a large collaborative studyof HIV-infected
individuals residing in Europe and North America, we
found that, among patients with baseline CD4þ cell count
at least 50 cells/ml, predicted mean CD8þ cell counts
continued to decrease between 3 and 15 years post-ART,
partly driving increases in the predicted mean
CD4þ : CD8þ ratio. Lower baseline CD4þ cell count
predicted higher increases in the mean CD4þ : CD8þ ratio
during the first 6 years since start of ART. Nonetheless,
even 15 years since start of ART, the mean CD4þ : CD8þ
ratio did not normalize among patients with baseline
CD4þ cell count less than 200 cells/ml.
Few studies have reported long-term trends in post-ART
CD8þ cell counts. Two years post-ART, two studies
reported similar findings to ours, of continued declines in
CD8þ cell counts [18,21], whereas three studies reported
stabilized CD8þ cell counts at elevated levels (approxi-
mately 600–900 cells/ml) [12,17,19]. However, sample
sizes in these studies were small compared with ours
(1253), and the patient population was heterogenous,
consisting of late presenters or a mixture of treatment
naı̈ve and treatment experienced patients.
Our findings regarding the CD4þ : CD8þ ratio were
similar to published small or restricted studies [18–
20,23,24,30,31]. Continued increases in the
CD4þ : CD8þ ratio for 8–15 years since start of treatment
have been reported among patients with sustained
undetectable viral loads [18,20,23]. Among patients with
baseline CD4þ cell counts greater than 350 cells/ml,
increases in the CD4þ : CD8þ ratio were partly attributed
to decreases in CD8þ cell counts [18–20]. In one study
examining CD4þ : CD8þ ratio trends by baseline CD4þ
cell count, lower baseline CD4þ cell count predicted
higher increases during the first 5 years after start of ART
[18]. Higher baseline CD4þ cell count predicted faster
time to normalized CD4þ : CD8þ ratio [30] and a greater
likelihood of attaining a normalized ratio [18,24,30,31].
In conclusion, there are long-term decreases in CD8þ cell
counts and long-term increases in CD4þ : CD8þ ratios,
among patients who start ART with CD4þ cell count as
low as 50–199 cells/ml. However, starting ART at high
CD4þ cell counts is paramount for attainment of a
maximal CD4þ : CD8þ ratio.Acknowledgements
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